Johnson & Johnson has paused the advanced clinical trial of its experimental COVID-19 vaccine after one of their 60,000 participants became ill. According to a statement from the pharmaceutical company, the participant’s “unexplained illness” is being reviewed and evaluated. Doctors must now determine whether the illness is linked to the vaccine or if it is a coincidence. In their statement, Johnson & Johnson stressed that “unexpected serious adverse event(s)”are an expected part of “any clinical study.” SAEs are not uncommon in clinical trials, and the number of SAEs can reasonably be expected to increase in trials involving large numbers of participants. , Johnson & Johnson, via statement. Dr. Ashish Jha of Brown University echoed their reassurance, saying a situation like this is “completed expected.” This is completely expected, and it's just a reminder how ridiculous it is to try and meet a political timeline of having a vaccine before Nov. 3, Dr. Ashish Jha, via CNN. This is the second Phase 3 COVID-19 vaccine trial to be paused in the United States. .AstraZeneca paused trials globally inSeptember after two British volunteers developed a serious neurological illness.